Source:http://linkedlifedata.com/resource/pubmed/id/16386399
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2-3
|
pubmed:dateCreated |
2006-2-28
|
pubmed:abstractText |
For the delivery of drugs into the brain, the use of nanoparticles as carriers has been described as a promising approach. Here, we prepared nanoparticles as carriers for the model drugs thioflavin T and thioflavin S that bind fibrillar amyloid beta peptides (Abeta). These polymer colloids are composed of a polystyrene core and a degradable PBCA [poly(butyl-2-cyanoacrylate)] shell with a diameter of 90-100nm as shown by dynamic light scattering. Fluorescence spectrophotometric analysis revealed that encapsulated thioflavin T exhibited significantly stronger fluorescence than the free fluorophore. The enzymatic degradation of core-shell nanoparticles, as required in vivo, was shown after their treatment with porcine liver esterase, a non-specific esterase, in vitro. Shells of nanoparticles were dose-dependently degraded while their polystyrene cores remained intact. In the cortices of 7-14 months old APP/PS1 mice with age-dependent beta-amyloidosis, thioflavins selectively targeted fibrillar Abeta after biodegradation-induced release from their nanoparticulate carriers upon intracerebral injection. Collectively, our data suggest that core-shell nanoparticles with controlled degradation in vivo can become versatile tools to trace and clear Abeta in the brain.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
0736-5748
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
24
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
195-201
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:16386399-Alzheimer Disease,
pubmed-meshheading:16386399-Amyloid,
pubmed-meshheading:16386399-Amyloid beta-Protein Precursor,
pubmed-meshheading:16386399-Animals,
pubmed-meshheading:16386399-Disease Models, Animal,
pubmed-meshheading:16386399-Dose-Response Relationship, Drug,
pubmed-meshheading:16386399-Drug Delivery Systems,
pubmed-meshheading:16386399-Hippocampus,
pubmed-meshheading:16386399-Mice,
pubmed-meshheading:16386399-Mice, Transgenic,
pubmed-meshheading:16386399-Nanostructures,
pubmed-meshheading:16386399-Neurofibrillary Tangles,
pubmed-meshheading:16386399-Protein Binding,
pubmed-meshheading:16386399-Thiazoles,
pubmed-meshheading:16386399-Time Factors
|
pubmed:articleTitle |
Thioflavins released from nanoparticles target fibrillar amyloid beta in the hippocampus of APP/PS1 transgenic mice.
|
pubmed:affiliation |
Department of Neurochemistry, Paul Flechsig Institute for Brain Research, University of Leipzig, Jahnallee 59, D-04109 Leipzig, Germany.
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|